Sorafenib and Bevacizumab in Treating Patients With Refractory, Metastatic, or Unresectable Solid Tumors - Contacts and Locations

Sorafenib and Bevacizumab in Treating Patients With Refractory, Metastatic, or Unresectable Solid Tumors

This study is ongoing, but not recruiting participants.

Study NCT00098592. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00098592

Locations


United States, Maryland
	NCI - Medical Oncology Branch
	Bethesda, Maryland, United States, 20892
	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
	Bethesda, Maryland, United States, 20892-1182

Sponsors and Collaborators

NCI - Center for Cancer Research-Medical Oncology

National Cancer Institute (NCI)

Investigators


Principal Investigator:	Elise C. Kohn, MD	NCI - Center for Cancer Research-Medical Oncology